Latest Regulatory News

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Ioneer Ltd has closed a $996 million loan from the U.S. Department of Energy to accelerate its Rhyolite Ridge Lithium-Boron Project in Nevada, following key federal permitting milestones. Construction is targeted for 2025, promising to boost domestic critical mineral supply and create hundreds of jobs.

A1 Investments & Resources Ltd reported a modest cash outflow for Q1 2024 while actively pursuing renewable energy acquisitions in Japan and Australia, contingent on regulatory approvals and shareholder consent.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Champion Iron Limited reported robust financial results for the nine months ended December 31, 2024, alongside a strategic partnership to develop its Kami Project with Nippon Steel and Sojitz.

Lanthanein Resources has completed initial drilling phases at its Lady Grey Project and secured a six-month extension on its farm-in agreement, positioning the company for a critical assessment of its gold exploration prospects.

Mach7 Technologies has initiated a A$5 million on-market share buy-back program, reflecting confidence in its robust financial health and growth outlook. The move underscores the company’s commitment to capital management amid reaffirmed FY25 revenue growth guidance.

Magnetite Mines Limited has made significant strides in advancing its Razorback Iron Ore Project, securing a $7 million funding facility and progressing strategic partnerships with JFE Shoji Australia. The company is also preparing to submit its Mining Lease Proposal to the South Australian Government amid a streamlined board and cost-cutting measures.